Voronoi, Inc. Logo

Voronoi, Inc.

Biotech firm developing therapeutics using an AI drug discovery platform.

310210 | KO

Overview

Corporate Details

ISIN(s):
KR7310210000
LEI:
Country:
South Korea
Address:
인천광역시 연수구 송도과학로 32 에스동 18층, 연수구

Description

Voronoi, Inc. is a biotechnology company that specializes in the research and development of novel therapeutics for challenging diseases. The company's core expertise lies in creating innovative small molecule kinase inhibitors and target protein degrader drugs. Utilizing its proprietary AI-powered drug discovery platform, VORONOMICS, Voronoi accelerates the identification and optimization of promising drug candidates. This platform enables the rapid design of therapies with high selectivity and brain penetration, primarily targeting various forms of cancer and other difficult-to-treat conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
투자판단관련주요경영사항 (VRN04 프로그램 연구에 대한 옵션 행사 및 자산 구매 계약 체결)
Korean 10.7 KB
2025-09-08 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 125.2 KB
2025-09-05 00:00
주식등의대량보유상황보고서(일반)
Korean 121.8 KB
2025-09-02 00:00
주식등의대량보유상황보고서(일반)
Korean 120.3 KB
2025-08-20 00:00
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (표피성장인자 수용체EGFR 돌연변이 비소세포폐암NSCLC 환자…
Korean 19.9 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.5 MB
2025-07-04 00:00
증권발행결과(자율공시)
Korean 5.6 KB
2025-06-30 00:00
주요사항보고서(전환사채권발행결정)
Korean 76.6 KB
2025-06-12 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-05-21 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-05-16 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-05-14 00:00
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (표피성장인자 수용체EGFR 돌연변이 비소세포폐암NSCLC 환자…
Korean 19.3 KB
2025-05-09 00:00
분기보고서 (2025.03)
Korean 1.5 MB
2025-05-08 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-03-28 00:00
정기주주총회결과
Korean 21.3 KB

Automate Your Workflow. Get a real-time feed of all Voronoi, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Voronoi, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Voronoi, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.